[go: up one dir, main page]

NO982988L - Middel for profylakse og behandling av diabetiske komplikasjoner - Google Patents

Middel for profylakse og behandling av diabetiske komplikasjoner

Info

Publication number
NO982988L
NO982988L NO982988A NO982988A NO982988L NO 982988 L NO982988 L NO 982988L NO 982988 A NO982988 A NO 982988A NO 982988 A NO982988 A NO 982988A NO 982988 L NO982988 L NO 982988L
Authority
NO
Norway
Prior art keywords
prophylaxis
treatment
diabetic complications
present
remedy
Prior art date
Application number
NO982988A
Other languages
English (en)
Other versions
NO982988D0 (no
NO316494B1 (no
Inventor
Yoshiharu Hayashi
Nobuharu Goto
Original Assignee
Yoshitomi Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yoshitomi Pharmaceutical filed Critical Yoshitomi Pharmaceutical
Publication of NO982988D0 publication Critical patent/NO982988D0/no
Publication of NO982988L publication Critical patent/NO982988L/no
Publication of NO316494B1 publication Critical patent/NO316494B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Dental Tools And Instruments Or Auxiliary Dental Instruments (AREA)
NO982988A 1995-12-27 1998-06-26 Anvendelse av forbindelse for fremstilling av medikament for profylakse og behandling av diabetiske komplikasjoner NO316494B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP34016195 1995-12-27
PCT/JP1996/003776 WO1997024333A1 (en) 1995-12-27 1996-12-24 Preventives/remedies for complications of diabetes

Publications (3)

Publication Number Publication Date
NO982988D0 NO982988D0 (no) 1998-06-26
NO982988L true NO982988L (no) 1998-08-26
NO316494B1 NO316494B1 (no) 2004-02-02

Family

ID=18334321

Family Applications (1)

Application Number Title Priority Date Filing Date
NO982988A NO316494B1 (no) 1995-12-27 1998-06-26 Anvendelse av forbindelse for fremstilling av medikament for profylakse og behandling av diabetiske komplikasjoner

Country Status (22)

Country Link
US (8) US6060496A (no)
EP (2) EP0881218B1 (no)
JP (1) JP3448869B2 (no)
KR (2) KR100471351B1 (no)
CN (2) CN1159009C (no)
AT (1) ATE252563T1 (no)
AU (1) AU716332B2 (no)
BG (1) BG63803B1 (no)
BR (1) BR9612316A (no)
CA (1) CA2241856C (no)
CZ (1) CZ294485B6 (no)
DE (1) DE69630465T2 (no)
EE (1) EE03524B1 (no)
ES (1) ES2210399T3 (no)
HU (1) HUP0000422A3 (no)
IL (1) IL125104A (no)
IS (1) IS4784A (no)
MX (1) MX9805317A (no)
NO (1) NO316494B1 (no)
NZ (1) NZ324454A (no)
RU (1) RU2173148C2 (no)
WO (1) WO1997024333A1 (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060496A (en) 1995-12-27 2000-05-09 Yoshitomi Pharmaceutical Industires, Ltd. Prophylaxis and treatment of diabetic complications with 4-[α-hydroxy-2-methyl-5-(1-imidazolyl) benzyl]-3,5-dimethylbenzoic acid
HUP0201485A3 (en) * 1999-05-25 2004-01-28 Mitsubishi Pharma Corp Osaka S Mag expression promoters
US6482844B1 (en) * 2000-04-07 2002-11-19 Neurogen Corporation 1-benzylimidazole derivatives
US6423309B1 (en) * 2000-11-24 2002-07-23 Toyo Shinyaku Co., Ltd. Composition containing grass plant, water-soluble dietary fibers, oligosaccharides, lactic acid bacteria and green tea
DE10229180A1 (de) 2002-06-28 2004-01-29 Aventis Pharma Deutschland Gmbh Verwendung von Vasopeptidase-Inhibitoren bei der Behandlung von metabolischen Erkrankungen, Nephropathie und mit AGE assoziierten Erkrankungen
AU2003270049A1 (en) * 2002-08-29 2004-03-19 University Of Florida Research Foundation Incorporated Cox-2 mediated altered prostaglandin balance in diabetes complications
GB0314945D0 (en) * 2003-06-26 2003-07-30 Black & Decker Inc Vacuum cleaner
TWI338583B (en) * 2004-05-20 2011-03-11 Otsuka Pharma Co Ltd Solid pharmaceutical formulation
AU2008350907A1 (en) 2007-12-11 2009-08-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
RU2741715C1 (ru) * 2020-03-20 2021-01-28 Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский государственный медицинский университет имени академика Е.А. Вагнера" Министерства здравоохранения Российской Федерации Способ прогнозирования формирования микрососудистых осложнений сахарного диабета 2 типа

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK531479A (da) * 1979-01-19 1980-07-20 Pfizer Fremgangsmaade til fremstilling af imidazolderivater og salte deraf
JPS61277670A (ja) * 1985-06-03 1986-12-08 Yoshitomi Pharmaceut Ind Ltd イミダゾ−ル誘導体
US4661603A (en) * 1982-03-03 1987-04-28 Yoshitomi Pharmaceutical Industries, Ltd. Imidazole derivatives
JPS6147477A (ja) * 1984-08-14 1986-03-07 Kowa Co 新規１，４−ジヒドロピリジン−３，５−ジカルボン酸エステル誘導体
JPS63119425A (ja) * 1986-11-07 1988-05-24 Yoshitomi Pharmaceut Ind Ltd 免疫機能改善薬
GB2205240B (en) * 1987-06-03 1991-01-09 Erba Carlo Spa N-imidazolyl derivatives of bicyclic compounds useful in medicine
WO1989006959A1 (fr) * 1988-02-03 1989-08-10 Yoshitomi Pharmaceutical Industries, Ltd. Preparation pharmaceutique a liberation amelioree
JP2814513B2 (ja) * 1988-02-03 1998-10-22 吉富製薬株式会社 溶出性の改良された製剤組成物
KR920700210A (ko) 1989-03-31 1992-02-19 기따미 가즈히꼬 신규 이미다졸 유도체, 그의 제법 및 그의 의약용도
JPH037281A (ja) * 1989-03-31 1991-01-14 Kyoto Yakuhin Kogyo Kk 新規イミダゾール誘導体およびその医薬用途
US5401851A (en) * 1992-06-03 1995-03-28 Eli Lilly And Company Angiotensin II antagonists
US6060496A (en) * 1995-12-27 2000-05-09 Yoshitomi Pharmaceutical Industires, Ltd. Prophylaxis and treatment of diabetic complications with 4-[α-hydroxy-2-methyl-5-(1-imidazolyl) benzyl]-3,5-dimethylbenzoic acid

Also Published As

Publication number Publication date
US6060496A (en) 2000-05-09
EP0881218B1 (en) 2003-10-22
ES2210399T3 (es) 2004-07-01
HUP0000422A2 (hu) 2001-04-28
NO982988D0 (no) 1998-06-26
BR9612316A (pt) 1999-07-13
WO1997024333A1 (en) 1997-07-10
AU1173597A (en) 1997-07-28
NZ324454A (en) 2000-09-29
DE69630465D1 (de) 2003-11-27
US20050239856A1 (en) 2005-10-27
US20040171663A1 (en) 2004-09-02
IL125104A (en) 2002-12-01
US20020169194A1 (en) 2002-11-14
KR20040045002A (ko) 2004-05-31
EE9800208A (et) 1998-12-15
DE69630465T2 (de) 2004-07-22
AU716332B2 (en) 2000-02-24
ATE252563T1 (de) 2003-11-15
CN1324618A (zh) 2001-12-05
IS4784A (is) 1998-06-26
BG63803B1 (bg) 2003-01-31
NO316494B1 (no) 2004-02-02
MX9805317A (es) 1998-10-31
EP0881218A4 (en) 1999-01-27
KR19990064262A (ko) 1999-07-26
US20060148875A1 (en) 2006-07-06
CN1159009C (zh) 2004-07-28
RU2173148C2 (ru) 2001-09-10
KR100471351B1 (ko) 2005-03-14
US20010036957A1 (en) 2001-11-01
HUP0000422A3 (en) 2001-06-28
IL125104A0 (en) 1999-01-26
CA2241856C (en) 2006-10-17
US6258834B1 (en) 2001-07-10
BG102633A (en) 1999-09-30
CN1209122A (zh) 1999-02-24
US20030130332A1 (en) 2003-07-10
HK1015777A1 (en) 1999-10-22
EE03524B1 (et) 2001-10-15
EP1394151A1 (en) 2004-03-03
JP3448869B2 (ja) 2003-09-22
CZ9802012A3 (cs) 1998-12-16
CA2241856A1 (en) 1997-07-10
EP0881218A1 (en) 1998-12-02
CZ294485B6 (cs) 2005-01-12
CN1092645C (zh) 2002-10-16
KR100443891B1 (ko) 2004-10-14

Similar Documents

Publication Publication Date Title
GEP20002298B (en) Benzimidazole Derivatives, Method of Their Production, Pharmaceutical Composition Containing the Same and Method for Its Treatment
EA200000468A1 (ru) Терапевтическая композиция для введения толтеродина с контролируемым высвобождением
DE69324466D1 (de) L-dopa Ester-enthaltende Zusammensetzung
CA2219115A1 (en) N-benzyl-3-indoleacetic acids as cyclooxygenase-2-inhibitors and antiinflammatory drugs
CA2106172A1 (en) Use of 2-(3,4-Dimethoxycinnamoyl)Aminobenzoic Acid for the Treatment of Restenosis Associated with Coronary Intervention
RU93032613A (ru) Фармацевтический препарат для лечения пациентов с пролонгированным временем коагуляции, способ лечения пациентов, применение epi ингибитора для получения фармацевтического препарата
UA35584C2 (uk) Лікарський засіб для лікування або профілактики ішемії міокарда та спосіб лікування ішемії міокарда у ссавців
NO982988L (no) Middel for profylakse og behandling av diabetiske komplikasjoner
MY129946A (en) Compound with gastric acid inhibitory effect and process for its preparation.
JPS6479117A (en) Azole antifungal agent
HUP9802897A2 (hu) Optikailag aktív piridil-4H-1,2,4-oxadiazin-származék, annak alkalmazása vaszkuláris betegségek kezelésére, valamint ilyen származékot hatóanyagként tartalmazó gyógyászati készítmény
HUT77135A (hu) Eljárás I típusú allergiás betegségek megelőzésére és kezelésére alkalmazható gyógyszerkészítmények előállítására
GB9216859D0 (en) Medicaments
AU4519189A (en) Medicaments for the treatment of toxoplasmosis
DE69727268D1 (de) Substanz fa-70d, herstellungsverfahren und verwendungen
RU94046312A (ru) Применение биологически активных уреидопроизводных для лечения индуцируемых лентивирусами заболеваний, продукты, содержащие уреидопроизводные
AU4519289A (en) Medicament for the treatment of cryptosporidiosis
AR009446A1 (es) Utilizacion del acido 2-(3,4-dimetoxinamoil)aminobenzoico (tranilast) en la fabricacion de un medicamento para el tratamiento o prevencion de larestenosis, composicion farmaceutica y procedimiento de preparacion.
DE60233578D1 (de) Phosphorenthaltende Verbindugnen mit antithrombitische Wirkung
TH20329A (th) สิ่งป้องกันโรคและสิ่งหรือยาใช้รักษาโรคสำหรับบาดแผล และ/หรือการอักเสบซึ่งเกี่ยวกับตา

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees